盐酸坦索罗辛治疗前列腺增生52例

目的探讨盐酸坦索罗辛对前列腺增生的临床治疗效果，分析其安全性。方法选择52例前列腺增生患者，分为重症组25例，轻症组27例，均给予口服盐酸坦索罗辛，每天1次，每次0．2mg。记录比较52例患者治疗前、连续服药治疗4周以及治疗半年后国际前列腺症状评分（IPSS）、最大尿流率（MFR）及前列腺大小的变化。结果治疗4周后，重症组患者23例有效，轻症组27例均有效，均无不良反应发生。重症组和轻症组的IPSS评分分别为（20．11±2．33）分、（10．51±1．03）分，MFR评分分别为（9．23±2．01）分、（11．63±1．31）分，与治疗前相比有明显改善（P〈0．05）。治疗半年后重症组和轻症组的前列腺体积分别为（33．71±5．23）mm3。和（29．57±4．45）mm3，与治疗前相比无明显变化（P〉0．05）。结论盐酸坦索罗辛对于改善前列腺增生患者的下尿路症状效果明显，且安全性高。

Tamsulosin in the Treatment of Benign Prostatic Hyperplasia in 52 Cases

Objective To study the treatment efficacy and safety of tamsulosin in treating benign prostatic hyperplasia. Methods Fifty- two cases of prostatic hyperplasia patients, divided into severe group （25 cases） and mild group （27 cases）, while giving the oral ad- ministration of tamsulosin hydrochloride, once a day, each time 0.2 mg. To record and compare 52 patients before treatment, continuous medication treatment for 4 weeks and 6 months after treatment of international prostate symptom score （IPSS）, maximal urinary flow rate （MFR） and prostatic size changes. Results After 4 weeks of treatment, 23 patients in severe group were effective, mild group 27 cases were all effective, there was no adverse reaction. Two groups of patients with IPSS scores were 20. 11±2.33 and 10.51 ±1.03, MFR scores were 9.23 ± 2.01 and 11.63 ± 1.31, compared with before treatment were significantly improved（ P 〈 0. 05）. Six months after treatment of prostate volume was 33.71 ±5.23 and 29.57±4.45, compared with before treatment showed no significant change（P〉 0.05）. Conclusion Tamsulosin hydrochloride on prostatic hyperplasia in patients with lower urinary tract symptoms are of evident effect and high safety.